The American Journal of Human Genetics, Volume 100

Supplemental Data

Duplicated Enhancer Region Increases Expression

of CTSB and Segregates with Keratolytic Winter

Erythema in South African and Norwegian Families

Thandiswa Ngcungcu, Martin Oti, Jan C. Sitek, Bjørn I. Haukanes, Bolan Linghu, Robert Bruccoleri, Tomasz Stokowy, Edward J. Oakeley, Fan Yang, Jiang Zhu, Marc Sultan, Joost Schalkwijk, Ivonne M.J.J. van Vlijmen-Willems, Charlotte von der Lippe, Han G. Brunner, Kari M. Ersland, Wayne Grayson, Stine Buechmann-Moller, Olav Sundnes, Nanguneri Nirmala, Thomas M. Morgan, Hans van Bokhoven, Vidar M. Steen, Peter R. Hull, Joseph Szustakowski, Frank Staedtler, Huiqing Zhou, Torunn Fiskerstrand, and Michele Ramsay



Figure S1. Validation of the tandem duplication in South African families with KWE

The tandem duplication at chr8:11729286-11736956 was analysed by PCR and Sanger sequencing (Table S1, Figure S2). Eleven affected and twelve non-affected individuals (*) from families F-I (pedigrees shown here) and individual I-1 from family C (Figure 1) were analysed. The duplication segregated completely with the disease. The pedigrees were drawn using HaploPainter V.1.043.¹



Figure S2. Mapping of duplication breakpoints in South African families. The breakpoints for the tandem duplication were determined by Pindel and visualized using the Integrative Genomics Viewer.² The junction sequence of the duplicated region is unique and was only present in individuals with the duplication. The picture shows gel electrophoresis of the PCR output using primer pairs for the duplication junction region (SA_Junction) and a control amplicon from the *LEP* gene (SA_Control). Primer sequences are shown in Table S1. The control amplicon (250 bp) is present in all samples and the duplication junction amplicon (375 bp) is present only in affected individuals (A), and not in unaffected individuals (NA).



Figure S3. CNVs in the KWE critical region reported in normal individuals. Schematic overview of the KWE critical region on chr8:11525326-11987757, with scale shown in the upper panel. Blue horizontal bars indicate duplications, red bars are deletions, and brown bars are both duplicated and deleted within the normal population. At the top, a large duplication identified in a Dutch cohort of 1416 healthy students³ and the tandem duplications identified in South African (7.67 kb) and Norwegian (15.93 kb) KWE patients are displayed as blue horizontal bars. The bottom track shows deletions and duplications in the healthy population from the Database of Genomic Variants, with accession numbers starting with "esv" or "nsv" depending on whether their source was the EBI or the NCBI. No duplications (blue bars) of similar size to those described in South African and Norwegian patients (turquoise shade across all panels) have been reported within the region. Several larger duplications (including the one in the Dutch cohort) are shown encompassing the region of the enhancer at chr8: 11734333-11736956 (large pink peak within the turquoise shade), but all of them include the *CTSB* gene and even the *FDFT1* gene, or the duplication does not extend to include the enhancer (nsv428195).



Figure S4. Topological subdomains, CTCF binding sites and chromatin interactions involving the enhancer and nearby genomic regions

Schematic overview of the KWE critical region on chr8:11560000-11880000, with scale shown in the upper panel. The South African (7.67 kb) and Norwegian (15.93 kb) tandem duplications are displayed as blue horizontal bars, and the 2.62 kb overlap (chr8:11734333-11736955) is marked across all horizontal panels (turquoise shading). (A) Hi-C data from the NHEK cell line (bold pink bars) placed the enhancer in the same topological region with the FDFT1 and CTSB genes. (B) CTCF binding sites in the keratinocyte (NHEK, pink peaks) and the breast cancer (MCF-7, black peaks) cell lines are highly similar. (C) Using the CTCF binding sites identified in NHEK cells, CTCF interaction loops (and hence subdomains) in these cells were predicted.⁴ These data indicate a larger subdomain extending from the strong CTCF binding site at the centromeric end of the NHEK Hi-C domain to the GATA4 gene, and a smaller subdomain, including only the enhancer and CTSB. (D) ChIA-PET CTCF data from MCF-7 cells showing that CTSB, FDFT1 and NEIL2 may occur in the same topological domain with the enhancer (Rep 1 (Repetition 1)). A smaller subdomain exists that only includes the CTSB gene and the enhancer (Rep 1 and 2). (E) MCF-7 Pol2 ChIA-PET interaction data show interaction between the enhancer and the CTSB promoter, but not with the promoters of FDFT1 or NEIL2 (Rep 3 and 4). Hi-C, CFCF-binding sites and ChIA-PET CTCF data are from the ENCODE data.⁵

Table S1. Primers used to verify South African and Norwegian tandem duplication breakpoints

Primer pairs	Primer Sequences (5' – 3')		Amplicon
			size
	Forward	Reverse	
SA_Junction [*]	CTAGGCTTGCAGTGTTGGTC	GTTAAATCAGGCTGGGCGAG	375 bp
SA_Control [*]	AGCCAAGGCAAAATTGAGG	TCCAGCCGATCTCTCTGTTC	250 bp
N_Junction**	GCCTGGCCACTTTCTTTCTT	GGTCATATGCTCAGGCAGGT	505 bp
N_Insertion**	CCGCATCCAGCATTTTTATT	CTGCTCCAAGTCACCCTCTC	624 bp

*Forward and reverse primers were selected for verification of the breakpoints in the South African duplication (SA_Junction) along with a control primer set (SA_control) overlapping the *LEP* gene. The SA_control primer pair was included in a multiplex PCR reaction to determine PCR efficiency. The breakpoint and the control amplicon were amplified using 1X KAPA TaqReadMix, 0.4 μ M of each primer and 0.1 μ g of genomic DNA. Cycling conditions included a 3 minute initial denaturation at 95°C, followed by 35 cycles of 30 seconds denaturation (95° C), 30 seconds annealing (55°C) and a 30 seconds extension at 72°C.

**In the Norwegian affected individuals, the duplication breakpoints were verified by WGS in two individuals, and Sanger sequencing demonstrated a tandem duplication (N_Junction primers) with a 95 bp insertion (i.e. triplication; N_Insertion primers) in between. PCR conditions: 1xATG 360 Mastermix, 0.5 μ M of each primer and 100 ng genomic DNA. Cycling conditions were as described above, except for a 10 min initial denaturation at 95°C.

					Fold	# of granular	
Sample	Status*	Sex	CTSB_CT**	<i>RPLP0</i> _CT**	change	layers	Intensity***
NOR _Ctr1	Ν	F	26.21	21.86	1.39	2	0
NOR _Ctr2	Ν	F	26.02	21.72	1.45	3	0
NOR _Ctr3	Ν	F	25.73	21.72	1.78	3-4	1
NOR _Ctr4	Ν	F	25.75	21.78	1.81	4	1
SA_Ctr1	Ν	F	28.70	22.48	0.38	4	0
SA _Ctr2	Ν	F	27.45	22.24	0.77	4	0
SA _Ctr3	Ν	М	27.96	22.19	0.52	3	0
NOR_DII-1	А	F	24.55	22.62	7.46	6	2.5
NOR_DII-6	А	F	24.65	22.77	7.77	4-5	2.5
NOR_DIII-6	А	F	24.22	22.05	6.29	4	1
NOR_EI-2	А	F	23.83	22.12	8.67	6	0.5
SA_KWE2	Α	М	24.57	21.55	3.49	5	2.5
SA_KWE3	А	М	26.19	22.37	2.02	5	2.5
SA_KWE1	А	F	no result	no result	no result	4	0.5

Fable S2: Relative gene expression	and immunohistochemistry	findings for CTSB
------------------------------------	--------------------------	-------------------

Average
foldStandard errors
of the meanControl (N)1.160.19Affected (A)5.950.93

* N=Not affected, A=Affected

** CT= Cycle threshold

*** Intensity of CTSB staining in the granular layer of the epidermis

Sample	Status*	Sex	FDFT1_CT**	RPLP0_CT**	Fold change
NOR _Ctr1	Ν	F	29.40	21.86	1.33
NOR _Ctr2	Ν	F	28.74	21.72	1.90
NOR _Ctr3	Ν	F	28.81	21.72	1.82
NOR _Ctr4	Ν	F	28.74	21.78	1.98
SA_Ctr1	Ν	F	31.45	22.48	0.49
SA _Ctr2	Ν	F	31.24	22.24	0.48
SA _Ctr3	Ν	М	31.25	22.19	0.46
NOR_DII-1	А	F	29.55	22.62	2.02
NOR_DII-6	А	F	30.09	22.77	1.54
NOR_DIII-6	А	F	29.19	22.05	1.74
NOR_EI-2	А	F	29.05	22.12	2.01
SA_KWE2	Α	М	28.98	21.55	1.43
SA_KWE3	Α	М	30.33	22.37	0.99

Table S3: Relative gene expression FDFT1

	Average fold change	Standard errors of the mean
Control (N)	1.21	0.22
Affected (A)	1.62	0.13

* N=Not affected, A=Affected

** CT= Cycle threshold

Sample	Status*	Sex	NEIL2_CT**	RPLP0_CT**	Fold change
NOR _Ctr1	N	F	29.91	21.86	2.17
NOR _Ctr2	Ν	F	29.75	21.72	2.21
NOR _Ctr3	Ν	F	29.24	21.72	3.15
NOR _Ctr4	Ν	F	30.70	21.78	1.19
SA_Ctr1	Ν	F	32.85	22.48	0.44
SA _Ctr2	Ν	F	32.54	22.24	0.46
SA _Ctr3	Ν	М	33.20	22.19	0.28
NOR_DII-1	А	F	30.86	22.62	1.90
NOR_DII-6	А	F	30.97	22.77	1.95
NOR_DIII-6	А	F	30.33	22.05	1.85
NOR_EI-2	А	F	29.64	22.12	3.11
SA_KWE2	Α	М	29.55	21.55	2.24
SA_KWE3	A	М	32.01	22.37	0.73

Table S4: Relative gene expression for *NEIL2*

	Average fold change	Standard errors of the mean	
Control (N)	1.41	0.30	
Affected (A)	1.96	0.22	

* N=Not affected, A=Affected

** CT= Cycle threshold

Supplemental References

- 1. Thiele, H., and Nurnberg, P. (2005). HaploPainter: a tool for drawing pedigrees with complex haplotypes. Bioinformatics 15, 1730-1732.
- 2. Robinson, J.T., Thorvaldsdottir, H., Winckler, W., Guttman, M., Lander, E.S., Getz, G., and Mesirov, J.P. (2011). Integrative genomics viewer. Nat Biotechnol 29, 24-26.
- Bralten, J., Arias-Vasquez, A., Makkinje, R., Veltman, J.A., Brunner, H.G., Fernandez, G., Rijpkema, M., and Franke, B. (2011). Association of the Alzheimer's gene *SORL1* with hippocampal volume in young, healthy adults. Am J Psychiatry 168, 1083-1089.
- 4. Oti, M., Falck, J., Huynen, M.A., and Zhou, H. (2016). CTCF-mediated chromatin loops enclose inducible gene regulatory domains. BMC Genomics 17, 252.
- 5. ENCODE Project Consortium. (2012). An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74.